Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab

Background The landmark study of durvalumab as consolidation therapy in NSCLC patients (PACIFIC trial) demonstrated significantly longer progression-free survival (PFS) in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) treated with durvalumab (immunotherapy, IO) ther...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Amit Gupta, Pingfu Fu, Nathan A Pennell, Mohamed Gad, Mohammadhadi Khorrami, Anant Madabhushi, Anas Saad, Pradnya Patil, Khalid Jazieh, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J Nock, Michael Gilkey
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMJ Publishing Group 2022-03-01
Serie:	Journal for ImmunoTherapy of Cancer
Accesso online:	https://jitc.bmj.com/content/10/3/e003778.full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab

Documenti analoghi